Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial

  1. D. J. Winston1,*,
  2. F. Saliba2,
  3. E. Blumberg3,
  4. M. Abouljoud4,
  5. J. B. Garcia-Diaz5,
  6. J. A. Goss6,
  7. L. Clough7,
  8. R. Avery8,
  9. A. P. Limaye9,
  10. B. G. Ericzon10,
  11. M. Navasa11,
  12. R. I. Troisi12,
  13. H. Chen13,
  14. S. A. Villano13,
  15. M. E. Uknis13,
  16. for the 1263–301 Clinical Study Group†

Article first published online: 4 SEP 2012

DOI: 10.1111/j.1600-6143.2012.04231.x

Issue

American Journal of Transplantation

American Journal of Transplantation

Volume 12, Issue 11, pages 3021–3030, November 2012

Additional Information

How to Cite

Winston, D. J., Saliba, F., Blumberg, E., Abouljoud, M., Garcia-Diaz, J. B., Goss, J. A., Clough, L., Avery, R., Limaye, A. P., Ericzon, B. G., Navasa, M., Troisi, R. I., Chen, H., Villano, S. A., Uknis, M. E. and for the 1263–301 Clinical Study Group (2012), Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial. American Journal of Transplantation, 12: 3021–3030. doi: 10.1111/j.1600-6143.2012.04231.x

Author Information

  1. 1

    Department of Medicine, UCLA Center for the Health Sciences, Los Angeles, CA

  2. 2

    Hospital Paul Brousse, Villejuif Cedex, France

  3. 3

    University of Pennsylvania, Philadelphia, PA

  4. 4

    Henry Ford Transplant Institute, Detroit, MI

  5. 5

    Ochsner Clinic Foundation, New Orleans, LA

  6. 6

    Baylor Collge of Medicine, Houston, TX

  7. 7

    University of Kansas Medical Center, Kansas City, KS

  8. 8

    Cleveland Clinic Foundation, Cleveland, OH

  9. 9

    University of Washington, Seattle, WA

  10. 10

    Karolínska Universĩtetssjukhúset-Huddinge, Stockholm, Sweden

  11. 11

    Hospital Clinic de Barcelona, Barcelona, Spain

  12. 12

    UZ Gent, Gent, Belgium

  13. 13

    ViroPharma, Inc., Exton, PA

  1. †

    †The Maribavir 1263-301 Clinical Study Group is listed in the Acknowledgement Section.

* Drew J. Winston, dwinston@mednet.ucla.edu

  1. †

    †The Maribavir 1263-301 Clinical Study Group is listed in the Acknowledgement Section.

Publication History

  1. Issue published online: 27 OCT 2012
  2. Article first published online: 4 SEP 2012
  3. Received 06 March 2012, revised 24 May 2012 and accepted for publication 06 June 2012
Corrected by:

Erratum: Erratum

Vol. 13, Issue 2, 529, Article first published online: 28 JAN 2013

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (643K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Get PDF (643K)